US Pharma MarketingASCO: Merck, Kelun's sac-TMT ADC combo beats Keytruda by 65% on progression in first-line lung cancer
Phase 3 data for Merck & Co. According to an abstract released ahead of the ASCO 2026 annual meeting, combining the TROP2-directed ADC with Keytruda slashed the risk of disease progression or death by a whopping 65% compared with Keytruda alone in treatment-naïve, PD-L1-positive non-small cell lung cancer. Biotech Cell & Gene Therapy Clinical Data Venture Capital Deals Research Medtech Devices Diagnostics AI and Machine Learning CRO Special Reports Trending Biologics Clinical Development Ophthalmology Cell & Gene Therapy Drug Development Small Molecule Research & Development Fierce 50 Special Report Awards Gala Awards Outsourcing Awards Innovation Awards Resources Fierce Events…
According to an abstract released ahead of the ASCO 2026 annual meeting, combining the TROP2-directed ADC with Keytruda slashed the risk of disease progression or death by a whopping 65% compared with Keytruda alone in treatment-naïve, PD-L1-positive non-small cell lung cancer.
Source: FierceBiotech